1. A single dose of recombinant VSV-∆G-spike vaccine provides protection against SARS-CoV-2 challenge
- Author
-
Hila Gutman, Shirley Lazar, Itai Glinert, Anat Zvi, Shmuel Yitzhaki, Tomer Israely, Noam Erez, Reut Puni, Shmuel C. Shapira, Einat B. Vitner, Shay Weiss, Dana Stein, Sharon Melamed, Inbar Cohen-Gihon, Haim Levy, Assa Sittner, Adi Beth-Din, Shlomi Lazar, Ohad Mazor, Yaron Vagima, Roy Avraham, Hagit Achdout, Boaz Politi, Ofir Israeli, Yfat Yahalom-Ronen, Nir Paran, Ran Zichel, Hadas Tamir, Edith Lupu, Lilach Cherry, Elad Milrot, Emanuelle Mamroud, Ohad Shifman, Elad Bar-David, Orly Laskar, and Amir Ben-Shmuel
- Subjects
0301 basic medicine ,viruses ,General Physics and Astronomy ,Antibodies, Viral ,law.invention ,0302 clinical medicine ,law ,Cricetinae ,skin and connective tissue diseases ,Antigens, Viral ,Lung ,Vaccines, Synthetic ,Vaccines ,Multidisciplinary ,biology ,Vaccination ,Viral Load ,030220 oncology & carcinogenesis ,Spike Glycoprotein, Coronavirus ,Recombinant DNA ,Antibody ,Viral load ,COVID-19 Vaccines ,Science ,Dose-Response Relationship, Immunologic ,Hamster ,Genome, Viral ,Vesicular stomatitis Indiana virus ,Article ,General Biochemistry, Genetics and Molecular Biology ,Cell Line ,03 medical and health sciences ,Antigen ,Animals ,SARS-CoV-2 ,fungi ,Body Weight ,COVID-19 ,General Chemistry ,Viral membrane ,Virology ,respiratory tract diseases ,body regions ,Mice, Inbred C57BL ,Disease Models, Animal ,030104 developmental biology ,Cell culture ,Mutation ,biology.protein - Abstract
The COVID-19 pandemic caused by SARS-CoV-2 imposes an urgent need for rapid development of an efficient and cost-effective vaccine, suitable for mass immunization. Here, we show the development of a replication competent recombinant VSV-∆G-spike vaccine, in which the glycoprotein of VSV is replaced by the spike protein of SARS-CoV-2. In-vitro characterization of this vaccine indicates the expression and presentation of the spike protein on the viral membrane with antigenic similarity to SARS-CoV-2. A golden Syrian hamster in-vivo model for COVID-19 is implemented. We show that a single-dose vaccination results in a rapid and potent induction of SARS-CoV-2 neutralizing antibodies. Importantly, vaccination protects hamsters against SARS-CoV-2 challenge, as demonstrated by the abrogation of body weight loss, and alleviation of the extensive tissue damage and viral loads in lungs and nasal turbinates. Taken together, we suggest the recombinant VSV-∆G-spike as a safe, efficacious and protective vaccine against SARS-CoV-2., Here, the authors generate a replication-competent VSV based vaccine expressing SARS-CoV-2 spike protein and show protection in the hamster model with one dose. Analysis of the antibody response in mice shows induction of neutralizing antibodies and suggests a desirable Th1-biased response to the vaccine.
- Published
- 2020